This guideline is departmental specific and applies only to activities within the Nephrology and Cardiology programs.

1.0 Introduction

This Clinical Practice Guideline (CPG) refers to the therapeutic plasma exchange for an infant/child with evidence of Antibody Mediated Rejection (AMR) after heart transplant. The goal of TPE is to remove donor-specific antibodies and/or inflammatory mediators implicated in AMR. The number of therapeutic plasma exchanges is patient specific and is ordered by the physician responsible for the patient's care. Please see Therapeutic Plasma Exchange under related documents for CPG on procedure.

The target users of this guideline will be Nurses, Physicians within the Nephrology and Cardiology programs.

Indications: This CPG applies to infants/children who have evidence of AMR.

Contraindications: Plasma exchanges should not ordinarily be performed within 24 hours of an operative procedure. If necessary to bypass this recommendation, the Staff M.D. must document the need for the procedure in the patient chart.

2.0 Definitions

- **Fresh Frozen Plasma (FFP)** - is separated from whole blood and is frozen within eight hours of collection. FFP contains all the coagulation factors in normal concentrations. Plasma is free of red blood cells, leukocytes and platelets. Plasma also has volume expansion and oncotic properties.

- **Total Blood Volume (TBV)** - the amount of blood in the whole body, both cells and fluid. The volume of the patient's blood is based on the patient's weight. The TBV is related to lean body mass. There is a difference between children and adults with newborns having a higher TBV per kg because of their higher packed red cell volume. TBV is calculated using the following formula:
  - Neonates (0-1 month): 100 ml/kg
  - Infants/children (1 month-16 years): 80 ml/kg
  - Adolescents (16 years and older): 70 ml/kg

- **Plasma Volume** is the total volume of plasma in the body.
  - Plasma Volume = TBV (ml) X (1-hematocrit)

- **Exchange** - patient plasma is replaced by donor plasma. The exchange product can be either FFP, 5% Albumin or a combination of both.
Heart Transplant - Antibody Mediated Rejection Therapeutic Plasma Exchange

3.0 Clinical Recommendations

**Pre-exchange requirements**
1. All recent post-transplant patients should be connected to cardiac monitor during plasma exchange.
2. Complete following blood work before the procedure:
   - C4D and differential
   - Ionized Ca
   - Albumin
   - K, Mg, P, Na
   - TCO2
3. Ensure blood work is within acceptable range.
4. Complete the following blood work after the procedure:
   - Ionized Ca
   - K, Mg, P
   - TCO2

**Replacement solution**
Replacement solution must be compatible with the patient’s serum blood type and the donor blood type. Refer to Blood Group Required for Blood Products Administered During ‘ABO Incompatible Heart Transplantation Plasma Exchange’ chart.

**Blood prime criteria**
- Patient weight > 20 kg
- eGFR > 30 ml/min
- Patient who is hemodynamically unstable
- ABO incompatibility

**Volume and number of exchanges**
1. Recommended volume of exchange is 1-1.5 times Plasma Volume.
2. Procedures to be performed daily for 5 days, then reassessed.
3. Improvement in cardiac function, biopsy findings, and donor specific antibody levels are used to determine timing of discontinuation.

**Measurement responses**
- ABO incompatible heart transplant dysfunction
- Increased donor specific antibodies
- HLA sensitized transplant with donor specific antibodies OR non-specific antibody mediated rejection.

**Blood groups required for blood products administered during incompatible heart transplantation**

©The Hospital for Sick Children ("SickKids"). All Rights Reserved. This document may be reproduced or used strictly for non-commercial clinical purposes. However, by permitting such use, SickKids does not grant any broader license or waive any of its exclusive rights under copyright or otherwise at law; in particular, this document may not be used for publication without appropriate acknowledgement to SickKids. This Clinical Practice Guideline has been developed to guide the practice of clinicians at the Hospital for Sick Children. Use of this guideline in any setting must be subject to the clinical judgment of those responsible for providing care. SickKids does not accept responsibility for the application of this guideline outside SickKids.
4.0 Related Documents:

Therapeutic Plasma Exchange Procedure
Management of Citrate Toxicity
Blood component Infusions

5.0 References

1. McLeod, B C Apheresis: Principles and Practice. 1997 (409-415)

Attachments:

Heart Transplant_care pathway_Feb 2022 (1).pdf